MCLA-117 [35], targeting C-type lectin domain family 12 member A (CLEC12A) and CD3, has demonstrated promising effects in the treatment of acute myeloid leukemia in phase I (Table 1). Here, CLEC12A is linked to acute myeloid leukemia.